A Phase 3 interventional study of Durvalumab and FLOT chemotherapy in Gastrointestinal Neoplasms and Esophagogastric Junction, sponsored by AstraZeneca. Active, not recruiting at 156 sites in 20 countries. Open to participants aged 18 Years to 200 Years. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Gastrointestinal Neoplasms with a site in Japan — 9 open to participants now, 12 under way, 5 of them phase 3. Gastrointestinal Neoplasms · Japan.
Among the 24 studies in Gastrointestinal Neoplasms with a site in Japan, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 11th registered.
696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.
Browse Gastrointestinal Neoplasms studies →9 of the 24 studies in Gastrointestinal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan
Ages 18+
Kansai Medical University · Sites in Japan
Ages 18+
Genmab · Sites in Japan, United States, Australia and 8 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Argentina and 14 more countries
Ages 18+
GlaxoSmithKline · Sites in Japan, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 200 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 9
First in 2007; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 957 is above the median of 74 across 495 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 243 across the 23 interventional studies, 300 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 24 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastrointestinal Neoplasms with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05489237IDRX, Inc., a wholly owned subsidiary of GSK, LLCFirst-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | 2027-03-10 |
| NCT07689201GlaxoSmithKlineA Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | 2027-11-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Gastrointestinal Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
This study investigates treatment of durvalumab or placebo therapy combined with FLOT chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery (neoadjuvant) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer, and also to better understand the studied disease and associated health problems.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo product and FLOT chemotherapy
Drug: FLOT chemotherapy
Durvalumab and FLOT chemotherapy
Drug: Durvalumab · Drug: FLOT chemotherapy
Human monoclonal antibody
Drug pages: Fluorouracil · Leucovorin · Oxaliplatin · Docetaxel
A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
Event-free survival (EFS)
EFS is the time from date of randomization until the date of disease progression or death.
Time frame: Up to 5 years
To compare Arm A relative to Arm B on overall survival (OS)
Overall survival is length of time from randomization until the date of death due to any cause.
Time frame: Up to 5 years
To compare Arm A relative to Arm B on pathological complete response (pCR) rate
pCR rate is the proportion of patients who have no residual viable tumor in the resected specimens.
Time frame: Up to 5 years
Showing the first 100 of 156 sites across 20 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2020 to primary completion in Dec 2024, 49 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab